$243 Million is the total value of Pivotal bioVenture Partners Investment Advisor LLC's 11 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | OCULIS HOLDING AGordinary shares | $17,692,286 | – | 2,381,196 | +100.0% | 7.28% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KARUNA THERAPEUTICS INC | 12 | Q3 2023 | 65.4% |
| VAXCYTE INC | 12 | Q3 2023 | 19.5% |
| INOZYME PHARMA INC | 12 | Q3 2023 | 10.8% |
| ARCUTIS BIOTHERAPEUTICS INC | 12 | Q3 2023 | 6.2% |
| FUSION PHARMACEUTICALS INC | 12 | Q3 2023 | 6.2% |
| ALIGOS THERAPEUTICS INC | 12 | Q3 2023 | 8.0% |
| BOLT BIOTHERAPEUTICS INC | 11 | Q3 2023 | 20.0% |
| RALLYBIO CORP | 9 | Q3 2023 | 14.1% |
| AKOUOS INC | 8 | Q3 2022 | 11.7% |
| EXSCIENTIA PLC | 8 | Q3 2023 | 6.4% |
View Pivotal bioVenture Partners Investment Advisor LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Pivotal bioVenture Partners Investment Advisor LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.